{
    "ticker": "ICCC",
    "name": "ImmunoCellular Therapeutics, Ltd.",
    "description": "ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for the treatment of cancer. Founded in 2008, the company aims to harness the power of the immune system to fight various forms of cancer, particularly through its proprietary technologies that target tumor-associated antigens. ImmunoCellular's lead product candidate, ICT-121, is an investigational treatment designed to enhance immune responses against glioblastoma, a notoriously aggressive brain cancer. The company is also exploring additional product candidates in its pipeline, including therapies targeting other solid tumors and hematological malignancies. With a commitment to advancing cancer immunotherapy, ImmunoCellular collaborates with research institutions and clinical partners to validate its therapeutic approaches and bring novel treatments to patients. The company's mission is to provide effective and safe cancer therapies that improve the quality of life for patients and their families.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2008",
    "website": "http://www.immunocellular.com",
    "ceo": "Manuel L. A. Velez",
    "social_media": {
        "twitter": "https://twitter.com/ImmunoCellular",
        "linkedin": "https://www.linkedin.com/company/immunocellular-therapeutics/"
    },
    "investor_relations": "http://www.immunocellular.com/investors",
    "key_executives": [
        {
            "name": "Manuel L. A. Velez",
            "position": "CEO"
        },
        {
            "name": "Gina S. Gibbons",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ICT-121",
                "ICT-140"
            ]
        }
    ],
    "seo": {
        "meta_title": "ImmunoCellular Therapeutics, Ltd. | Innovative Cancer Immunotherapies",
        "meta_description": "Explore ImmunoCellular Therapeutics, Ltd., a biotechnology company dedicated to developing immune-based therapies for cancer treatment. Learn about their innovative approaches and ongoing clinical trials.",
        "keywords": [
            "ImmunoCellular Therapeutics",
            "Cancer Immunotherapy",
            "ICT-121",
            "Biotechnology",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does ImmunoCellular Therapeutics focus on?",
            "answer": "ImmunoCellular Therapeutics focuses on developing immune-based therapies for the treatment of cancer."
        },
        {
            "question": "What is ICT-121?",
            "answer": "ICT-121 is an investigational treatment designed to enhance immune responses against glioblastoma."
        },
        {
            "question": "Where is ImmunoCellular headquartered?",
            "answer": "ImmunoCellular is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "When was ImmunoCellular founded?",
            "answer": "ImmunoCellular was founded in 2008."
        }
    ],
    "competitors": [
        "NK",
        "CLDX",
        "IMGN",
        "AXSM"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "BMY"
    ]
}